Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy

Tumori

Volumn 99, Issue 1, 2013, Pages 93-99

  Yeo, Seung Gu ^a,b   Kim, Dae Yong ^a   Chang, Hee Jin ^a   Park, Ji Won ^a   Oh, Jae Hwan ^a   Kim, Byung Chang ^a   Baek, Ji Yeon ^a   Kim, Sun Young ^a   Kim, Tae Hyun ^a  

^a National Cancer Center   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Carcinoembryonic antigen; Preoperative chemoradiotherapy; Rectal cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE TREATMENT; PROTEIN BLOOD LEVEL; RECTUM CANCER; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; BLOOD; FACTORIAL ANALYSIS; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECTUM TUMOR; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FACTOR ANALYSIS, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84878124137     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1248.13795     Document Type: Article

References (33)

1. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP: American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer, 88: 1739-1757, 2000.
2. American Joint Committee on Cancer. Colon and Rectum. In: AJCC Cancer Staging Manual, 7th edn, Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (Eds), pp 143-164, Springer, New York, 2010.
3. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, Oettgen HF: Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med, 299: 448-451, 1978.
4. Carriquiry LA, Pineyro A: Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum, 42: 921-929, 1999.
5. Park YJ, Youk EG, Choi HS, Han SU, Park KJ, Lee KU, Choe KJ, Park JG: Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors. Int J Colorectal Dis, 14: 101-106, 1999.
6. Lindmark G, Bergstrom R, Pahlman L, Glimelius B: The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer, 71: 1090-1094, 1995.
7. Peng JJ, Cai SJ, Lu HF, Cai GX, Lian P, Guan ZQ, Wang MH, Xu Y: Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers. World J Gastroenterol, 13: 3009-3015, 2007.
8. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 351: 1731-1740, 2004.
9. Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, Park JW, Oh JH, Lim SB, Choi HS, Jeong SY: Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Oncol Biol Phys, 77: 1158-1165, 2010.
10. Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JH, Park W, Choi DH, Nam H, Kim JS, Cho MJ, Kim JH, Park JH, Kang MK, Koom WS, Nam TK, Chie EK, Lee KJ: Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg, 252: 998-1004, 2010.
11. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, Paty PB, Weiser MR, Klimstra D, Saltz L, Minsky BD, Wong WD: Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg, 241: 829-838, 2005.
12. Coco C, Valentini V, Manno A, Mattana C, Verbo A, Cellini N, Gambacorta MA, Covino M, Mantini G, Micciche F, Pedretti G, Petito L, Rizzo G, Cosimelli M, Impiombato FA, Picciocchi A: Long-term results after neoadjuvant radiochemotherapy for locally advanced resectable ex-traperitoneal rectal cancer. Dis Colon Rectum, 49: 311-318, 2006.
13. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR: Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer, 113: 57-64, 2008.
14. Shivnani AT, Small W, Jr., Stryker SJ, Kiel KD, Lim S, Halverson AL, Talamonti MS: Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg, 193: 389-393, 2007.
15. Onaitis MW, Noone RB, Hartwig M, Hurwitz H, Morse M, Jowell P, McGrath K, Lee C, Anscher MS, Clary B, Mantyh C, Pappas TN, Ludwig K, Seigler HF, Tyler DS: Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. Ann Surg, 233: 778-785, 2001.
16. American Joint Committee on Cancer. Colon and Rectum. In: AJCC Cancer Staging Manual, 6th edn, Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (Eds), pp 113-123, Springer-Verlag, New York, 2002.
17. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 12: 19-23, 1997.
18. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, Jr: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol, 24: 5313-5327, 2006.
19. Duffy MJ: Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem, 47: 624-630, 2001.
20. Myerson RJ, Singh A, Birnbaum EH, Fry RD, Fleshman JW, Kodner IJ, Lockett MA, Picus J, Walz BJ, Read TE: Pretreatment clinical findings predict outcome for patients receiving preoperative radiation for rectal cancer. Int J Radiat Oncol Biol Phys, 50: 665-674, 2001.
21. Chan AK, Wong A, Jenken D, Heine J, Buie D, Johnson D: Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys, 61: 665-677, 2005.
22. Ishihara S, Watanabe T, Kiyomatsu T, Yasuda K, Nagawa H: Prognostic significance of response to preoperative radiotherapy, lymph node metastasis, and CEA level in patients undergoing total mesorectal excision of rectal cancer. Int J Colorectal Dis, 25: 1417-1425, 2010.
23. Nagtegaal ID, Quirke P: What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol, 26: 303-312, 2008.
24. Perez RO, Sao Juliao GP, Habr-Gama A, Kiss D, Proscurshim I, Campos FG, Gama-Rodrigues JJ, Cecconello I: The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum, 52: 1137-1143, 2009.
25. Jang NY, Kang SB, Kim DW, Kim JH, Lee KW, Kim IA, Kim JS: The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. Dis Colon Rectum, 54: 245-252, 2011.
26. Park JW, Lim SB, Kim DY, Jung KH, Hong YS, Chang HJ, Choi HS, Jeong SY: Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol Phys, 74: 810-817, 2009.
27. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH: Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer, 109: 1750-1755, 2007.
28. Yoon SM, Kim DY, Kim TH, Jung KH, Chang HJ, Koom WS, Lim SB, Choi HS, Jeong SY, Park JG: Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys, 69: 1167-1172, 2007.
29. Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, Cho CW: Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol, 93: 145-150, 2006.
30. Yeo SG, Kim DY, Kim TH, Kim SY, Chang HJ, Park JW, Choi HS, Oh JH: Local excision following pre-operative chemoradiotherapy-induced downstaging for selected cT3 distal rectal cancer. Jpn J Clin Oncol, 40: 754-760, 2010.
31. Yeo SG, Kim DY, Kim KH, Ku JL, Kim JS, Cho MJ, Kim ES, Yoo BC: Hydroxymethylglutaryl-coenzyme A synthase 2 expression is associated with chemoradiotherapy responses in colorectal cancer. Dis Colon Rectum, 55: 686-694, 2012.
32. Weissenberger C, Von Plehn G, Otto F, Barke A, Momm F, Geissler M: Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9. Anticancer Res, 25: 1787-1793, 2005.
33. Riesterer O, Milas L, Ang KK: Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol, 25: 4075-4083, 2007.